The article presents the author's views on metastatic prostate cancer (mPC) management. Topics discussed include using Androgen deprivation therapy (ADT) for the treatment of men with mPC, prolonged usage of ADT leading to severe side effects such as hot flashes and decresaed energy level and use of chemotherapeutic agents like mitoxantrone and docetaxel and clinical trials being conducted for patients with castration resistant prostate cancer (CRPC).